The estimated Net Worth of Klaus Schafer is at least $166 Tisíc dollars as of 20 June 2022. Klaus Schafer owns over 279 units of Altimmune Inc stock worth over $65,813 and over the last 7 years he sold ALT stock worth over $100,587. In addition, he makes $0 as Independent Director at Altimmune Inc.
Klaus has made over 4 trades of the Altimmune Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 279 units of ALT stock worth $670 on 20 June 2022.
The largest trade he's ever made was exercising 16,850 units of Altimmune Inc stock on 24 September 2020 worth over $120,815. On average, Klaus trades about 2,662 units every 58 days since 2017. As of 20 June 2022 he still owns at least 9,179 units of Altimmune Inc stock.
You can see the complete history of Klaus Schafer stock trades at the bottom of the page.
Brig. Gen. (Retd.) Klaus O. Schafer M.D. serves as Independent Director of the Company. Dr. Schafer has over 30 years of leadership experience, having held senior positions in government and industry. He was first elected to Altimmune’s board of directors in July 2012. As the Deputy Asst. to the Secretary of Defense for chemical and biological defense, a position he held from April 2004 through June 2005, he oversaw the management of the Department of Defense’s $1.0 billion program for vaccine, therapeutics, medical device and sensor development. He retired from the Air Force as the Assistant Surgeon General with extensive experience managing all aspects of large integrated health care delivery systems. Prior private sector experience includes VP of business development for Compressus Inc., a telemedicine start-up, former CEO and cofounder of TessArae LLC, a start-up biotech genetic testing company, Chief Medical Officer and VP, business development, Health for CACI International, a publicly traded Fortune 1000 company, and consultant and advisory board member to numerous companies and to the biodefense industry. Dr. Schafer earned his MD at the University of Iowa, Family Practice Boards, Eglin AFB where he was Chief Resident, MPH at the University of Texas and the Master of Science at the Eisenhower School of National Security and Resource Strategy. Dr. Schafer was selected as a director for his board and varied background, including deep understanding of government biotech development strategy, funding, and budgeting, and his commercial industry experiences. Dr. Schafer brings significant experience as a physician and biotechnology investor, in government and as a board member and advisor in the health care biodefense industry to Altimmune’s board of directors.
Klaus Schafer is 70, he's been the Independent Director of Altimmune Inc since 2017. There are 2 older and 12 younger executives at Altimmune Inc. The oldest executive at Altimmune Inc is David Drutz, 81, who is the Independent Director.
Klaus's mailing address filed with the SEC is C/O ALTIMMUNE, INC.,, 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG, MD, 20878.
Over the last 7 years, insiders at Altimmune Inc have traded over $2,557,810 worth of Altimmune Inc stock and bought 3,362,060 units worth $23,898,779 . The most active insiders traders include Bioventures Ltd Novartis Ag..., Healthcare Capital Partners... a Mitchel Sayare. On average, Altimmune Inc executives and independent directors trade stock every 35 days with the average trade being worth of $432,889. The most recent stock trade was executed by David Drutz on 19 August 2024, trading 41,750 units of ALT stock currently worth $106,463.
altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current
Altimmune Inc executives and other stock owners filed with the SEC include: